A study published in Nature Communications has found that semaglutide, a GLP-1 drug, may slow biological aging in adults with HIV. Conducted by researchers at the University of California, San Diego, the study involved 108 participants, half of whom received semaglutide while the other half received a placebo. Results indicated that those treated with semaglutide experienced a 9% slower biological aging rate compared to the placebo group. The study highlights the potential of GLP-1 drugs to influence aging processes, although further research is needed to validate these findings and assess their applicability to the general population.
Key facts
- The study involved 108 adults with HIV-associated lipohypertrophy.
- Participants treated with semaglutide showed a 9% slower biological aging pace.
- The study tracked cellular aging over a 32-week period.
- Semaglutide significantly reduced biological processes linked to all-cause mortality.
- Future studies will explore the effects of GLP-1 drugs on aging biology.
A short AI summary in our own words. The reporting belongs to Hacker News — Front Page; we don't reproduce it.